Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 10:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lactobacillus casei Clear all
Completed Phase 3 Interventional Results available

ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT02773849
View directory record Official record
Conditions
Superficial Bladder Cancer
Interventions
ADSTILADRIN
Biological
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
34
States / cities
Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 23, 2026, 10:49 AM EDT
Completed Not applicable Interventional

Engineering Gut Microbiome to Target Breast Cancer

NCT03358511
View directory record Official record
Conditions
Breast Cancer
Interventions
Probiotic
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 23, 2026, 10:49 AM EDT
Not yet recruiting Phase 2 Interventional

A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

NCT07559175
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
Interventions
NHS7108, Zenpep®
Drug
Lead sponsor
Aimmune Nestlé Health Science US R&D, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Scottsdale, Arizona • Los Angeles, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 23, 2026, 10:49 AM EDT
Active, not recruiting Phase 2 Interventional

Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years

NCT05866536
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes, Diabetes type1, Autoimmune Diabetes
Interventions
Bacillus Calmette-Guérin, Saline Injection
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 23, 2026, 10:49 AM EDT
Active, not recruiting Phase 3 Interventional

Intravesical BCG vs GEMDOCE in NMIBC

NCT05538663
View directory record Official record
Conditions
Non-muscle-invasive Bladder Cancer
Interventions
Gemcitabine, Docetaxel, Bacillus Calmette Guerin
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
229
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 163 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 23, 2026, 10:49 AM EDT
Completed Phase 2 Interventional Results available

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

NCT02015104
View directory record Official record
Conditions
Bladder Cancer
Interventions
BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG)), PANVAC
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Sep 23, 2026, 10:49 AM EDT
Recruiting Phase 3 Interventional

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

NCT06545955
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Interventions
Nadofaragene Firadenovec, Gemcitabine, Docetaxel, Pembrolizumab
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
39
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 23, 2026, 10:49 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

NCT04452591
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Interventions
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
Biological · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
45
States / cities
Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 23, 2026, 10:49 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

NCT04640623
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
TAR-200, Cetrelimab
Drug · Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Sherman Oaks, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 23, 2026, 10:49 AM EDT
Terminated Phase 3 Interventional Results available

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

NCT04149574
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
nivolumab, Placebo, Bacillus Calmette-Guérin (BCG)
Drug · Other · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Chicago, Illinois • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 23, 2026, 10:49 AM EDT
Recruiting Phase 1Phase 2 Interventional

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

NCT06704191
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
Interventions
BCG Solution, Cystoscopy, Docetaxel, Gemcitabine, Home Health Encounter, Mitomycin, Questionnaire Administration
Biological · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 23, 2026, 10:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Synbiotic on the Gut Microbiota and Adiposity-related Markers in Healthy Overweight Subjects

NCT02151825
View directory record Official record
Conditions
Gut Microbiota, Adiposity
Interventions
Synbiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Texas State University, San Marcos
Other
Eligibility
18 Years to 64 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Marcos, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Sep 23, 2026, 10:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Modulation of Type 1 Diabetes Susceptibility Through the Use of Probiotics

NCT03423589
View directory record Official record
Conditions
Type1diabetes, Type1 Diabetes Mellitus
Interventions
VSL#3
Dietary Supplement
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
5 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Sep 23, 2026, 10:49 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Alcoholic Liver Disease and the Gut Microbiome

NCT05007470
View directory record Official record
Conditions
Alcohol Use Disorder, Alcoholic Liver Disease, Microbiome
Interventions
VSL #3 112.5 Capsule, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2025 · Synced Sep 23, 2026, 10:49 AM EDT
Recruiting Phase 1Phase 2 Interventional

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

NCT04752722
View directory record Official record
Conditions
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
Interventions
EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy)
Drug
Lead sponsor
enGene, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 23, 2026, 10:49 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT

NCT02010203
View directory record Official record
Conditions
Bladder Cancer
Interventions
HS-410, Placebo, BCG
Biological
Lead sponsor
Heat Biologics
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
19
States / cities
Los Angeles, California • Sherman Oaks, California • Torrance, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 23, 2026, 10:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of a Novel Probiotic on Gastrointestinal Health in Generally Healthy Adults

NCT05595980
View directory record Official record
Conditions
Gastrointestinal Health, Immune Health, Digestive Health
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
BIO-CAT Microbials, LLC
Industry
Eligibility
30 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Sep 23, 2026, 10:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Plasma Amino Acid Response to Whey Protein Ingestion Following 28-days of Probiotic Supplementation

NCT04491188
View directory record Official record
Conditions
Focus of Study is Amino Acid Appearace in Blood
Interventions
Bacillus subtilis DE111, Placebo
Dietary Supplement
Lead sponsor
Lipscomb University
Other
Eligibility
18 Years to 34 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Sep 23, 2026, 10:49 AM EDT
Terminated Not applicable Interventional Results available

Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection

NCT02202044
View directory record Official record
Conditions
Bladder Carcinoma
Interventions
Intravesical BCG and EMDA/MMC
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Phoenix, Arizona • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 23, 2026, 10:49 AM EDT
Recruiting Phase 2 Interventional

Synbiotic Compound to Reduce Symptoms of Schizophrenia

NCT04226898
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Synbiotic Supplement, Inert Compound
Biological
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Batlimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 23, 2026, 10:49 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of a 5-Week Probiotic Supplementation Intervention on Markers of Delayed Onset Muscle Soreness

NCT07219498
View directory record Official record
Conditions
Exercise Induced Muscle Damage, Delayed Onset Muscle Soreness (DOMS)
Interventions
Lactobacillus casei, Placebo Capsule(s)
Dietary Supplement · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 30 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 23, 2026, 10:49 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections

NCT05606159
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
Bacillus velezensis DSM 33864, Placebo
Dietary Supplement
Lead sponsor
Novozymes A/S
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 23, 2026, 10:49 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Biological Samples Obtained by Leukapheresis Induced by Two BCG Vaccinations in BCG-naïve Healthy Adults in the US

NCT03175380
View directory record Official record
Conditions
Tuberculosis
Interventions
bacillus Calmette-Guérin
Biological
Lead sponsor
Aeras
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 23, 2026, 10:49 AM EDT
Completed Not applicable Interventional

Evaluation of Jarro-Dophilus EPS® Probiotic Formulations

NCT02693314
View directory record Official record
Conditions
Healthy
Interventions
Jarro-Dophilus EPS® (5 billion CFU/capsule), Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule), Placebo
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 23, 2026, 10:49 AM EDT